Genentech cancer, ophthalmic news

Sen. Herb Kohl (D-Wis.) is investigating DNA's plans to limit the availability of Avastin bevacizumab to compounding pharmacies, which prepare the cancer drug for off-label use in wet age-related macular degeneration (AMD) and other ocular diseases (see BioCentury, Nov. 5 & Oct. 15). ...